Searched for: in-biosketch:true
person:vso201
Severe Striae Distensae in the Setting of Pediatric Nephrotic Syndrome [Case Report]
Cohen, Koral; Oza, Vikash; Malaga-Dieguez, Laura
Striae distensae, or stretch marks, are common dermal scars resulting from skin overstretching. This case series documents the occurrence of severe striae in three pediatric patients with nephrotic syndrome. This report details the clinical manifestations, including widespread and edematous striae, and explores potential etiological factors such as rapid skin stretching from edema and high-dose corticosteroid use underlying this association.
PMID: 40785667
ISSN: 1525-1470
CID: 5906812
Alopecia in Children with Cancer: A Review from Pathophysiology to Management
Kearney, Caitlin A; Maguire, Ciara A; Oza, Vikash S; Oh, Christina S; Occidental, Michael A; Shapiro, Jerry; Orlow, Seth J; Glasser, Chana L; Lacouture, Mario E; Lakdawala, Nikita R; Lo Sicco, Kristen I
Chemotherapy-induced alopecia and radiation-induced alopecia, the thinning or loss of hair due to cytotoxic chemotherapy and radiation therapy, respectively, are distressing adverse effects of cancer treatment. Chemotherapy, targeted therapies, and radiation therapy used in pediatric oncology often lead to alopecia by damaging hair follicles, with varying degrees of severity depending on the specific treatment type, mechanism of action, and damage-response pathway involved. Pediatric chemotherapy-induced alopecia, radiation-induced alopecia, and permanent alopecia, defined as hair regrowth that remains incomplete 6 months or more after treatment, have significant negative impacts on mental health, self-esteem, and social interactions, highlighting the need for further research into supportive care strategies. There are currently no standard interventions for chemotherapy-induced alopecia or radiation-induced alopecia in children, with most recommendations limited to gentle hair care and camouflaging techniques during treatment. Scalp cooling has demonstrated safety and efficacy in reducing chemotherapy-induced alopecia in adults and is currently under investigation in children and adolescents. Topical and low-dose oral minoxidil have been studied in children for other hair loss disorders and may improve hair regrowth after chemotherapy or radiation. Increased awareness and continued research into management strategies for pediatric chemotherapy-induced alopecia and radiation-induced alopecia are necessary to help mitigate its significant negative impact on quality of life.
PMID: 40587083
ISSN: 1179-1888
CID: 5887592
Monoclonal antibody targeting IFNβ for the treatment of NXP2-positive ulcerative juvenile dermatomyositis
Guirguis, Justina; Ramachandran, Vignesh; Ann Vleugels, Ruth; Greenberg, Steven A; Kim, Hanna; Kahn, Philip J; Oza, Vikash
This report outlines the case of a 9-year-old girl with severe anti-nuclear matrix protein 2 antibody-positive juvenile dermatomyositis presenting with disease refractory to multiple traditional therapies. Treatment with an experimental monoclonal antibody inhibiting interferon beta (IFNβ) resulted in the rapid resolution of her muscle weakness and cutaneous and gastrointestinal ulcers. This case highlights the potential benefit of inhibiting IFNβ in the management of recalcitrant juvenile dermatomyositis.
PMID: 40112879
ISSN: 1098-4275
CID: 5813612
Exploring the Rise in Pediatric "Skincare Routines" on Social Media [Letter]
Brinks, Anna L; Needle, Carli D; Pulavarty, Akshay; Kearney, Caitlin A; Maguire, Ciara A; Calderón, Daniela; Sharoff, Aditya N; Shapiro, Jerry; Orlow, Seth J; Lo Sicco, Kristen I; Oza, Vikash S
PMID: 39803709
ISSN: 1365-4632
CID: 5776242
Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib
Needle, Carli D; Yin, Lu; Young, Trevor K; Friedman, Steven; Mandal, Soutrik; Segal, Devorah; Yohay, Kaleb H; Lakdawala, Nikita R; Oza, Vikash S
BACKGROUND:Binimetinib and selumetinib are two mitogen-activated protein kinase kinase (MEK) inhibitors used to treat low-grade gliomas and plexiform neurofibromas. Cutaneous toxicities are commonly associated with MEK inhibitors; however, limited studies have examined cutaneous effects in a pediatric population or whether toxicities vary between MEK inhibitors. METHODS:We conducted an IRB-approved, single-center, retrospective review of pediatric neuro-oncology patients on binimetinib or selumetinib who presented to NYU from April 2016 through July 2022. RESULTS:Forty-six children met inclusion criteria (23 females, 23 males) with a mean age of 11.7 years. Thirty-three were treated with binimetinib and 13 with selumetinib. Dermatologic adverse events were encountered in 97.8% of the cohort, and the most common were acneiform eruption (63.0%), paronychia (58.7%), and xerosis (54.3%). Children 12 years and older were more likely to have acneiform eruption (p < 0.001) and seborrheic dermatitis (p < 0.001), while children under 12 were more likely to have xerosis (p = 0.037). The incidence of cutaneous adverse events was significantly different between MEK inhibitors for folliculitis and hair pigment dilution (39.4% binimetinib, 0% selumetinib, p = 0.009). Significantly, more patients required MEK inhibitor dose reduction/hold on binimetinib (87.9%) than selumetinib (46.2%) (p = 0.006). Severity of cutaneous disease was not associated with tumor response. CONCLUSIONS:Our study confirms dermatologic adverse events are common in children on MEK inhibitors. Age appears to be associated with increased likelihood of certain cutaneous reactions. Overall, the selumetinib patients in our cohort presented with less severe adverse events and decreased risk of MEK inhibitor dose reduction/hold. Our results will aid clinicians in providing appropriate counseling, treatments, and improved preventive care.
PMID: 39511793
ISSN: 1525-1470
CID: 5752132
Anifrolumab in recalcitrant cutaneous dermatomyositis: A multicenter retrospective cohort study
Shaw, Katharina S; Hashemi, Kimberly B; Castillo, Rochelle L; Rainone, Elizabeth; Ho, Allen W; Kahn, Philip J; Oza, Vikash S; Femia, Alisa; Vleugels, Ruth Ann
PMID: 39142472
ISSN: 1097-6787
CID: 5726892
A gain-of-function variant in SREBF1 causes generalized skin hyperpigmentation with congenital cataracts [Case Report]
Wang, Huijun; Wu, Yuan; Bassetti, Jennifer A; Wang, Zhaoyang; Oza, Vikash S; Rangu, Sneha A; McGivern, Bobbi; Peng, Sha; Liang, Lina; Huang, Shimiao; Gong, Zhuoqing; Xu, Zigang; Lin, Zhimiao
BACKGROUND:Lipid metabolism has essential roles in skin barrier formation and the regulation of skin inflammation. Lipid homeostasis regulates skin melanogenesis, although the underlying mechanism remains largely unknown. Sterol regulatory element binding protein 1 (SREBP-1) is a key transcription factor essential for cellular lipid metabolism. Loss-of-function variants in SREBF1 are responsible for autosomal-dominant ichthyosis follicularis, alopecia and photophobia syndrome, emphasizing the significance of lipid homeostasis in skin keratinization. OBJECTIVES/OBJECTIVE:To identify the genetic basis of a new entity featuring diffuse skin hyperpigmentation with congenital cataracts, and to unravel the underlying mechanism for the pathogenesis of the SREBF1 variant. METHODS:Whole-exome sequencing was performed to identify underlying genetic variants. Quantitative polymerase chain reaction, Western blot and immunofluorescence staining were used to assess the expression and the subcellular localization of the SREBF1 variant. The transcriptional activity of mutant SREBP-1 was determined by a luciferase reporter assay. A transgenic zebrafish model was constructed. RESULTS:Two unrelated patients presented with generalized skin hyperpigmentation with skin xerosis, congenital cataracts and extracutaneous symptoms. We identified a de novo nonsense variant c.1289C>A (p.Ser430*) in SREBF1 in both patients. The variant encoded a truncated protein that showed preferential nucleus localization, in contrast to wild-type SREBP-1 which - in sterol-sufficient conditions - is mainly localized in the cytoplasm. The luciferase reporter assay revealed that the p.Ser430* mutant exhibited enhanced transcriptional activity. Cultured patient primary melanocytes showed increased melanin synthesis vs. those from healthy controls. At 35 days postfertilization, the p.Ser430* transgenic zebrafish model exhibited more black spots, along with upregulated expression of melanogenic genes. CONCLUSIONS:We demonstrated that a gain-of-function variant of SREBF1 causes a previously undescribed disorder characterized by generalized skin hyperpigmentation and congenital cataracts. Our study reveals the involvement of SREBP-1 in melanogenesis and lens development, and paves the way for the development of novel therapeutic targets for skin dyspigmentation or cataracts.
PMID: 39005171
ISSN: 1365-2133
CID: 5711362
Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature
Iriarte, Christopher; Yeh, Jennifer E; Alloo, Allireza; Boull, Christina; Carlberg, Valerie M; Coughlin, Carrie C; Lara-Corrales, Irene; Levy, Rebecca; Nguyen, Cuong V; Oza, Vikash S; Patel, Anisha B; Rotemberg, Veronica; Shah, Sonal D; Zheng, Lida; Miller, Corinne H; Hlobik, Madeline; Daigneault, Jaclyn; Choi, Jennifer N; Huang, Jennifer T; Vivar, Karina L
BACKGROUND:MEK inhibitors cause a wide spectrum of mucocutaneous toxicities which can delay or interrupt life-saving therapy. PURPOSE/OBJECTIVE:To summarize the morphology, incidence, and clinical presentation of mucocutaneous toxicities from MEK inhibitors via a scoping review of the literature. METHODS:We conducted a scoping review of the published literature, including clinical trials, retrospective and prospective studies, reviews, and case reports and series. All included literature was analyzed by a panel of pediatric and adult oncodermatologists. RESULTS:Of 1626 initial citations, 227 articles met final inclusion criteria. Our review identified follicular reactions, ocular toxicities, xerosis, eczematous dermatitis, edema, and paronychia as the most common mucocutaneous side effects from MEK inhibitor therapy. Grade 1 and 2 reactions were the most prevalent and were typically managed while continuing treatment; however, grade 3 toxicities requiring dose reductions or treatment interruptions were also reported. CONCLUSION/CONCLUSIONS:Mucocutaneous toxicities to MEK inhibitor therapy are common and most often mild in severity. Early recognition and treatment can mitigate disruptions in oncologic therapy.
PMID: 39174797
ISSN: 1433-7339
CID: 5681072
Appearance Dissatisfaction and Body Dysmorphic Disorder in the Dermatology Patient
Sejdiu, Zane; Stitzlein, Erin; Rieder, Evan A; Andriessen, Anneke; Greenberg, Jennifer L; Oza, Vikash S; Cutler, Vanessa; Gonzalez, Mercedes E; Lio, Peter; Love, Elyse M; Park, Joyce; Andriessen, Hinke; Phillips, Katharine A
Dermatologists routinely see patients with inflammatory skin conditions and aesthetic concerns that involve substantial psychological comorbidity. However, most dermatologists do not receive formal training in this area, and many are unsure how to best help treat certain patients holistically. Body dysmorphic disorder (BDD) is a common and distressing psychiatric condition that disproportionately impacts dermatology patients, including patients living with chronic inflammatory skin conditions such as acne and atopic dermatitis. BDD is characterized by preoccupation with nonexistent or minimally noticeable flaws in physical appearance that cause clinically significant distress or impairment in functioning. Adolescent populations may be particularly vulnerable to clinically significant body image dissatisfaction, including BDD, due to the high prevalence of acne and the pervasive role of social media platforms. The rise of social media may exacerbate body image issues through repetitive exposure to idealized and often unrealistic beauty standards. Though screening questionnaires can assist dermatologists in recognizing BDD, dermatologists must collaborate with mental health providers to provide comprehensive care to vulnerable patients, including adolescents.J Drugs Dermatol. 2024;23(7):545-550. doi:10.36849/JDD.8156.
PMID: 38954625
ISSN: 1545-9616
CID: 5698282
That New Shoe Smell: Allergic Contact Dermatitis to Fragrance in Shoes
Jairath, Neil K; Oza, Vikash S; Milam, Emily C
PMID: 37279024
ISSN: 2162-5220
CID: 5627942